/COMUNICAE/
This is an example of collaboration between Biolan Health and Quirónsalud Bizkaia Hospital, within the framework of the OSASUNBERRI initiative that promotes the incorporation of kilometer 0 innovation into the Basque health system
• Lactose intolerance affects 20 per cent of the population.
• The new test, developed in collaboration with VENTER PHARMA, allows early detection in a safe and comfortable way for the patient, compared to those existing today.
Basque companies BIOLAN HEALTH and HOSPITAL QUIRÓNSALUD BIZKAIA, in collaboration with VENTER PHARMA, present a new test in urine for early detection of lactose intolerance in a simple and reliable way. Lactose intolerance affects, according to the Spanish Foundation of Digestive Aparatus, between 20% and 40% of the population and occurs due to the lack of an enzyme called intestinal lactase causing nausea, abdominal pain or diarrhea in these patients.
Until now, the tests to detect lactose intolerance were to make the patient ingest a lactose preparation and later a blood test or hydrogen test in the breath, an action that is annoying to the patient. However, the development of BIOLAN HEALTH's OSAXYL biosensor, together with the PHARMA's LACTEST drug, offers a disruptive solution for the detection of this intolerance faster and more harmlessly, an innovation in which the Hospital QUIRONSALUD of Bizkaia is committed.
People who have hypolactasia, as called this disease, have various symptoms after the intake of lactose products ranging from abdominal pain, gases and diarrhea, to vomiting, but symptoms vary depending on the amount ingested and the level of intolerance. Therefore, the launch of this shared initiative will be launched at the Hospital QUIRÓNSALUD Bizkaia offering patients of the center, this diagnostic test, and expecting satisfactory results very soon.
This joint initiative has been promoted as a result of the launch of the OSASUNBERRI project which seeks to facilitate a collaborative environment for innovation among health sector companies. The objective of OSASUNBERRI is to combine efforts and strengthen the health sector of Km 0, with the development and incorporation of innovative solutions in the health system and investment in research and competitive productive infrastructures.
About WHO
Quirónsalud is the leading hospital group in Spain and, together with its Fresenius-Helios matrix, also in Europe. In addition to its activity in Spain, Quirónsalud is also present in Latin America, particularly in Colombia and Peru. Together, it has more than 45,000 professionals in more than 160 health centres, including 55 hospitals with approximately 8,000 hospital beds. It has the most advanced technology and a great team of highly specialized and internationally renowned professionals. Among its centers are the Hospital Universitario Fundación Jiménez Díaz, Centro Médico Teknon, Ruber Internacional, Hospital Universitario Quirónsalud Madrid, Hospital Quirónsalud Barcelona, Hospital Universitario Dexeus, Policlínica Gipuzkoa, Hospital Universitari General de Catalunya, Hospital Quirónsalud Sagrado Corazón, etc.
The Group works in the promotion of teaching (nine of its hospitals are university students) and medical-scientific research (accounts with the FJD Health Research Institute, accredited by the State Secretariat for Research, Development and Innovation).
In addition, its assistance service is organized in units and cross-sectional networks that allow for the optimization of the accumulated experience in the various centers and the clinical translation of their research. Currently, Quirónsalud is developing a multitude of research projects throughout Spain and many of its centers carry out in this area a leading work, being pioneers in different specialties such as oncology, cardiology, endocrinology, gynaecology and neurology, among others.
About BIOLAN HEALTH
BIOLAN HEALTH is the health division of BIOLAN Microbiosensors created after the identification of an interesting opportunity for the diversification of your business into the health market. It aims to offer to the market devices and solutions based on enzyme biosensors and fast, reliable and cost-efficient side-flow immunossays with in vitro diagnostic application, for the monitoring and detection of parameters of interest that help to make effective decisions in the diagnosis, prevention and monitoring of health.
BIOLAN HEALTH offers personalized services, ad hoc solutions to pharmaceutical companies, biotechnology companies, hospitals and care centers, clinical analysis laboratories, universities, and research centers with the need to analyze parameters of interest in a fast, economic and reliable way.
The BIOLAN Group has a multidisciplinary team consisting of highly qualified professionals and specialized infrastructures, so that the union of these excellent capacities allows to offer unique solutions, with high precision and simplicity and highly competitive. BIOLAN is a company with a global vocation that is committed to continuous innovation, self-manufacturing and marketing, with a worldwide presence through 9 commercial delegations distributed throughout the planet.
Two Basque companies launch a new test in Euskadi that will allow early detection of lactose intolerance
This is an example of collaboration between Biolan Health and Quirónsalud Bizkaia Hospital, within the framework of the OSASUNBERRI initiative that promotes t
nails
en
https://cdnimages.juegosboom.com/nails-trends.com/1220/dbmicrodb2-nails-two-basque-companies-launch-a-new-test-in-euskadi-that-will-allow-early-detection-of-lactose-intolerance-654-0.jpg
2023-04-11
Acording with the Digital Millennium Copyright Act (“DMCA”), Pub. L. 105-304 If you believe that your copyrighted work is being infringed, notify our team at the email [email protected]